Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist. 1981

A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008090 Lisuride An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS). Lysuride Hydrogen Maleate,Methylergol Carbamide,Arolac,Cuvalit,Dopergin,Dopergine,Lisuride Hydrochloride,Lisuride Maleate,Lisuride Maleate (1:1),Lisuride Maleate, (8beta)-Isomer,Lisuride Mesylate,Lisuride Phosphate (1:1),Lisuride, (8alpha)-(+-)-Isomer,Lysenyl,Lysurid,Revanil,Carbamide, Methylergol,Hydrochloride, Lisuride,Hydrogen Maleate, Lysuride,Maleate, Lisuride,Mesylate, Lisuride
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
March 1989, Neurology,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
May 2009, Journal of movement disorders,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
January 1995, Journal of neural transmission. Supplementum,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
August 2005, Movement disorders : official journal of the Movement Disorder Society,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
January 1986, European neurology,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
January 1992, Acta histochemica. Supplementband,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
January 1986, Clinical and experimental neurology,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
January 1984, Advances in neurology,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
December 2003, Current opinion in neurology,
A N Lieberman, and M Goldstein, and A Neophytides, and M Leibowitz, and G Gopinathan, and A Goodgold, and V Pact, and R Walker
November 2007, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Copied contents to your clipboard!